Nordea Investment Management AB Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Nordea Investment Management AB raised its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 40.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 148,700 shares of the company's stock after purchasing an additional 43,100 shares during the quarter. Nordea Investment Management AB owned approximately 0.18% of CRISPR Therapeutics worth $10,305,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. ARK Investment Management LLC increased its stake in shares of CRISPR Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company's stock valued at $534,360,000 after buying an additional 1,372,986 shares during the period. Capital International Investors increased its stake in shares of CRISPR Therapeutics by 0.8% in the 4th quarter. Capital International Investors now owns 6,134,450 shares of the company's stock valued at $384,017,000 after buying an additional 48,938 shares during the period. Vanguard Group Inc. increased its stake in shares of CRISPR Therapeutics by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 1,590,651 shares of the company's stock valued at $99,575,000 after buying an additional 51,926 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of CRISPR Therapeutics by 2.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company's stock valued at $40,879,000 after buying an additional 15,085 shares during the period. Finally, Norges Bank acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $38,661,000. Institutional investors own 69.20% of the company's stock.

Analyst Upgrades and Downgrades

CRSP has been the subject of a number of analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Guggenheim reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Oppenheimer decreased their price objective on CRISPR Therapeutics from $102.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, May 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $88.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, June 27th. Finally, Wells Fargo & Company decreased their price objective on CRISPR Therapeutics from $70.00 to $65.00 and set an "equal weight" rating for the company in a research note on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $75.71.

CRISPR Therapeutics Trading Up 3.4 %

Shares of CRISPR Therapeutics stock traded up $1.80 during trading on Tuesday, reaching $55.03. The stock had a trading volume of 902,827 shares, compared to its average volume of 1,621,100. The company has a market capitalization of $4.67 billion, a price-to-earnings ratio of -20.23 and a beta of 1.70. The stock has a fifty day moving average price of $56.58 and a two-hundred day moving average price of $64.09. CRISPR Therapeutics AG has a 52 week low of $37.55 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. During the same quarter in the previous year, the firm earned ($0.67) EPS. The business's quarterly revenue was down 99.5% compared to the same quarter last year. On average, equities analysts forecast that CRISPR Therapeutics AG will post -5.51 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Julianne Bruno sold 3,366 shares of the company's stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares in the company, valued at $378,327.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the business's stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares of the company's stock, valued at $12,468,589.02. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Julianne Bruno sold 3,366 shares of the business's stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.